Sarepta Therapeutics shares dropped 20% after a patient's death raises Elevidys safety concerns. Read why I am downgrading SRPT stock to Hold from Buy.

Sarepta Therapeutics (SRPT) stock drops 25% as the company reports a patient death linked to Elevidys, its gene therapy developed with Roche (RHHBY). Read more here.

Things are going from bad to worse for Sarepta Therapeutics (NASDAQ: SRPT), a biotech focusing on gene therapies. The company ...

Shares of Sarepta Therapeutics SRPT plunged more than 20% yesterday after the company reported the death of a patient after treatment with Elevidys, its one-shot gene therapy for Duchenne muscular ...

Sarepta’s commercial partner, Roche, recorded 184 million Swiss francs in total Elevidys sales last year outside the U.S. The biotech does not expect the latest death event will have an impact ...

Roche (RHHBY) announced that it will present new data at the Muscular Dystrophy Association, MDA conference, 16-19 March, 2025, in Dallas, ...

At week 104, MRI changes from baseline continued to generally favour Elevidys versus placebo at week 52 across muscles and muscle groups. Further information on the abstracts that Roche will ...

Roche leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics. Elevidys is the first approved disease-modifying gene therapy for Duchenne and ...

Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...

Elevidys has been developed by Sarepta in partnership with pharma giant Roche RHHBY. SRPT and RHHBY entered into a licensing agreement in 2019 to develop Elevidys. Per the agreement, Roche has ...

Muscle pathology as measured by MRI continued to generally favour Elevidys across muscle groups in boys with Duchenne up to two years Basel, 17 March 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) ...

We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.